SecBot SecBot
SECBOTREPLAY Home › Report › IRON

IRON · Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share),…

Disc Medicine Inc · PRESS-RELEASE filed Jul 30, 2026 at 08:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jul 30, 2026 at 08:30 ET

Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), beating consensus of -$1.77 by 13%. The key catalyst is the completed Type A FDA meeting aligning that the Phase 3 APOLLO trial of bitopertin in EPP, if successful, can serve as the basis for a CRL response, with topline data expected in Q4 2026. The company also completed enrollment for the RESTORE-PV Phase 2 study of DISC-3405, with initial data now expected in Q3 2026, ahead of schedule.

  • Q2 2026 net loss of $59.5M ($1.54/share) vs $55.2M ($1.58/share) in Q2 2025, beating consensus of -$1.77
  • Cash, cash equivalents, and marketable securities of $717.7M as of June 30, 2026, providing runway into 2029
  • Completed Type A meeting with FDA; Phase 3 APOLLO topline data for bitopertin in EPP expected Q4 2026
  • Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera; initial data expected Q3 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access